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ACRONYMS AND ABBREVIATIONS 
 
AnTx  anuroctoxin 
APA  action potential amplitude 
APD50  action potential duration measured at 50% of repolarization 
APD90  action potential duration measured at 90% of repolarization 
C. majus Chelidonium majus 
CHO-K1 Chinese hamster ovary K1 cell line 
DEA  desethylamiodarone 
DMEM Dulbecco's modified Eagle's medium 
DMSO dimethyl sulfoxide 
EC50  half maximal effective concentration 
EDTA  ethylenediaminetetraacetic acid 
EGTA  ethylene glycol tetraacetic acid 
FBS  fetal bovine serum 
GABA gamma-aminobutyric acid 
GIRK  G protein-coupled inwardly rectifying potassium channel 
GTPγS guanosine-5'-(γ-thio)-triphosphate 
HEK293 human embryonic kidney 293 cell line 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HCN  hyperpolarization-activated cyclic nucleotide-gated channel 
hERG  human ether-a-go-go-related gene 
ICa,L  L-type Ca
2+
 current 
If  funny or pacemaker current 
IKACh  acetylcholine receptor operated potassium current  
IKr  rapid delayed rectifier potassium current 
IKs  slow component of the delayed rectifier potassium current 
Ito  transient outward potassium current 
IC50  half maximal inhibitory concentration 
IMDM Iscove's modified Dulbecco's medium 
MEM  minimum essential medium 
MgTx  margatoxin 
PBS  phosphate buffered saline 
TEA  tetraethylammonium 
RP  resting potential 
RPMI 1640 Roswell Park Memorial Institute 1640 medium 
RP-silica gel reversed-phase silica gel 
RP-HPLC reversed-phase high-performance liquid chromatography 
RT  room temperature 
Vmax  maximum upstroke velocity 
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1. INTRODUCTION 
 
1.1. Ion channels in drug research and discovery 
 
Ion channels are a large and diverse family of transmembrane pore-forming proteins present 
in a large variety of cell types [1][2][3][4][5][6][7]. They facilitate the rapid passive transport 
of specific inorganic ions (such as Na
+
, K
+
, Ca
++
 and Cl
-
) through the lipid bilayers of plasma 
and organelle membranes down their electrochemical gradient that is established by the work 
of pumps and transporters [1][5][6][7][8][9].  
Defined by the stimulus necessary to evoke activity, the majority of ion channels are 
commonly classified into two main subgroups: voltage-gated and ligand-gated channels. The 
most important difference is that voltage-gated ion channels are activated by changes in 
plasma membrane potential, while ligand-gated channels activated by endogenous ligands 
[3][4][5][10]. In addition, there are ion channels activated by mechanic force and hot or cold 
stimuli [3][4][5]. Ion channels are also grouped into various subclasses by another key 
functional characteristic, their selective permeability to different ions [7][8][11]. Voltage-
gated ion channels are rather specific for the various cations and anions. Therefore, these 
channels are typically named after the ion for which they are selective for. Ligand-gated ion 
channels are regularly named after the ligand essential for their activation [4]. 
A functional ion channel consists of one or more α-subunits, forming an aqueous pore. 
Auxiliary β and γ subunits associate with the α-subunits and modify their properties including 
gating, membrane surface expression, pharmacology and selectivity. The number of identified 
proteins that create the ion permeation pathways is around 300. The typical heteromultimeric 
assembly of the pore-forming subunits further elevates the number of possible combinations. 
In addition, more than 100 auxiliary proteins are known up to date. The heteromultimeric 
α-subunits and their association with various auxiliary subunits together can give rise to a 
very large number of functional ion channel protein complexes [5][7][9][10][11]. 
Ion channels regulate a variety of physiological processes. They provide the base for 
membrane excitability thus they are prominent components of both the nervous and the 
cardiovascular system. Ion channels determine excitability of neurons and muscles by 
controlling the creation and propagation of action potentials, release of neurotransmitters, and 
setting up cardiac rhythm and muscle tone. In non-excitable cells, they play fundamental roles 
in hormone secretion, enzyme activation, gene expression, immune response and in cell 
replication, development and volume regulation [1][4][5][7][8][11][12]. 
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Because of their pivotal role, ion channel dysfunction has adverse effects on physiology, and 
could lead to many severe chronic and acute diseases and disorders, so-called 
channelopathies. Since the diversity of ion channels is extremely high in excitable cells, 
including heart, skeletal, and smooth muscles as well as in the central and peripheral nervous 
system, most of channelopathies have been identified in these tissues. Functional 
abnormalities of ion channels are known to cause cardiovascular dysfunctions (such as life-
threatening cardiac arrhythmias and hypertension) and neurological disorders (multiple 
sclerosis, epilepsy, migraine, schizophrenia, depression, neuropathic pain and diabetic 
neuropathy). Additional examples of channelopathies are cystic fibrosis, kidney malfunction 
and type II diabetes [2][3][4][5][7][8][9][11]. Furthermore, each year more and more ion 
channels are identified and linked to diseases [10]. 
Most of these common diseases are primarily treated by drugs that pharmacological modulate 
ion channel functions, therefore ion channels represent a highly attractive class of molecular 
targets for both academic research and pharmaceutical industry [1][2][7][9]. As membrane-
bound proteins they are accessible for small molecule treatment and are highly ‘druggable’ 
targets. This is primarily due to the various binding sites and many possible interactions that 
the ion channels offer. Ion channels currently represent the third largest target class of 
pharmaceutical agents (only overtaken by G-protein coupled and nuclear receptors). 
Approximately 13-15% of the top selling drugs on the market exert their effects through ion 
channels, reflecting their importance [1][3][4][5][9][10][11][12]. Within the pharmaceutical 
and biotechnology industry today, enormous efforts and resources are spent on ion channel 
drug screening, to discover and develop new and more effective medications [4]. 
Another important aspect of drug development programmes and ion channel drug screening is 
the safety evaluation of potential candidate molecules to assess possible adverse drug effects. 
Particularly important are the possibility of cardiovascular side effects, since several 
compounds exert their arrhythmogenic effects through the ion channel encoded by the human 
ether-a-go-go-related gene (hERG), expressed in cardiac ventricular myocytes, which has 
shown to be extremely promiscuous in its interactions with drugs. The inhibition of hERG 
channel may delay cardiac action potential repolarization, which can result in the prolongation 
of the QT interval on the ECG and increase the risk of potentially fatal ventricular 
arrhythmias, which had been the reason for the withdrawal of several would-be ‘blockbuster’ 
drugs from the market. At present, every new drug must go through preclinical safety testing 
determined by the U. S. Food and Drug Administration, the European Medicines Agency and 
other regulatory entities [1][2][4][7][12][13][14]. 
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1.2. Methods of ion channel research 
 
Despite their physiological importance and therapeutic relevance, ion channels remained an 
underexploited drug target class for a long time. Ion channels have historically been difficult 
to screen due to the limitations of methods. The available assay technologies cannot provide 
simultaneously the throughput and quality of data and put a trade-off between high-
throughput and high-information content [1][5][10][11][12]. 
 
1.2.1. Conventional intracellular techniques 
 
Conventional intracellular recordings involve a group of methods used to measure with 
accuracy the voltage across the cellular membranes by inserting an electrode inside the cell. 
Intracellular recordings can be performed with glass microelectrodes filled with conductive 
medium inserted through the membrane with negligible damage to the interior of the cell. 
This makes it possible to record the potential difference between the intracellular milieu and 
an extracellular reference point [15], presented on Figure 1A. However, electrophysiological 
techniques impaling a cell with a fine electrode can directly measure only the transmembrane 
voltage and its changes called action potential, but not the current flow through individual ion 
channels which serve as the basis of the transmembrane potential changes. 
 
       
Figure 1. Schematic drawing of different electrophysiological techniques. Panel A shows the intracellular method 
which used to record the transmembrane potential by inserting a glass microelectrode into a cell and recording 
the potential changes with respect to an extracellular reference electrode. Panel B presents the classical patch-
clamp configuration uses a micropipette attached to the cell membrane. In whole-cell configuration, by applying 
brief suction, the patch of membrane covering the pipette tip can be ruptured and currents can be measured from 
the entire ion channel population. Planar patch-clamp (panel C) is a novel method developed for high-throughput 
electrophysiology. Instead of positioning a pipette on an adherent cell, cell suspension is pipetted on a chip 
containing a microaperture where the cell is positioned by suction. 
 
1.2.2. Conventional manual patch-clamp 
 
Transmembrane ionic currents have been measured since 1952 after the pioneering work of 
Hodgkin and Huxley [16][17][18][19][20] who were awarded by Nobel Prize in 1963 [21]. 
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However, it was not possible to use their methods for voltage-clamp experiments in most 
tissues because the cells are too small. Today, ion channels are most precisely studied using 
the conventional patch-clamp technique. By this method, measurement of the activity of 
individual channels or the entire ion channel population of the cell became possible. The well-
established patch-clamp method developed by Erwin Neher and Bert Sakmann in the late 
1970s [22][23] (Nobel prize in 1991 [24]). The patch-clamp technique has rapidly become the 
‘gold standard’ in studying ion channel behaviour, function, kinetics and pharmacology in 
vitro, both in native or cultured mammalian cells [2][3][5][7][9][10][12][25]. 
A borosilicate glass microelectrode was patched onto the surface of a single cell and the ionic 
current passing through the enclosed ion channels in the plasma membrane was measured. 
The key requirement for performing such recordings is to form a ‘gigaseal’, where ‘giga’ 
denotes the extremely resistive tight interaction (several gigaohm) that is formed between the 
microelectrode and the lipid membrane, which enables fine quality recording of currents with 
high signal-to-noise ratio [1][2][3][4][12]. Neher and Sakmann accomplished their 
experiments in the cell-attached configuration in order to study the behaviour of single 
channels. However, by applying brief suction after the gigaohm seal is achieved, the patch of 
membrane covering the pipette tip can be ruptured, resulting in the most popular whole-cell 
configuration of patch-clamping. The direct access to the interior of the cell enables for 
voltage control of the cell membrane and allows modulating the intracellular environment. In 
this configuration, currents are measured from the entire ion channel population present in the 
cell membrane (Figure 1B). Voltage protocols and administration of drugs are tools used to 
analyse and characterize the ion channels expressed in a cell [2][4]. 
The patch-clamp is the only method which offers a direct, information-rich and real-time 
technology to study ion channel behaviour, function and regulation. Although providing 
excellent data quality, conventional patch-clamp also has disadvantages. Throughput in 
manual patch-clamp suffers severely from its laborious nature. It requires the continuous 
presence of a highly skilled, trained and patient operator. The fact that it takes years to acquire 
the soft skills necessary for operating the system also needs to be considered. These factors 
lead to the increase in price of data points. The typical throughput of conventional patch-
clamping is approximately five to ten data points per day allowing the characterization of only 
a limited number of compounds per week. This very low data throughput excludes manual 
patch-clamp as a screening tool in early drug development and optimization, since in these 
drug screening phases require a much greater throughput [1][2][3][4][7][9][10].  
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1.2.3. Ion channel screening with high-throughput systems 
 
Due to the limitations in throughput of manual patch-clamp, high-throughput techniques are 
also required and become integral components for primary drug screening and ion channel 
drug discovery programmes. These methodologies are based on cell-free, non-functional 
ligand binding or cell-based, functional radioactive flux and fluorescence (ion- or voltage-
sensitive dyes) assays. Although these approaches are compatible with the throughput 
requirements of primary screening and have been useful in supporting the efforts to identify 
and profile compounds, the high data quality was sacrificed to gain high throughput. Most of 
these methods have low fidelity, low sensitivity and low temporal resolution. High-throughput 
techniques often require extensive assay development and are known to have high rates of 
false-negative and false-positive results. Some techniques are not suitable for measurements 
on all ion channels since in several cases the readout is coupled to specific ion species, like 
calcium-sensitive dyes while other methods like the rubidium efflux assay require the use of 
radioactive compounds. Lacking voltage control over the cell membrane sometimes offer a 
challenge to investigate the channels activated by the change in transmembrane voltage. On 
the positive side, these assay techniques allow the screening of up to 100.000 compounds or 
more in a limited time frame and require less specialized operators [2][3][4][5][7][9][10][11]. 
 
1.2.4. Automated patch-clamp systems 
 
In recent years, numerous companies have developed and introduced automated patch-clamp 
platforms suitable for rapid and high quality screening and optimization of ion channel drug 
candidates. This new technology aims to extract functional data on ion channel active 
compounds with the throughput capability that is 10- to 10.000-fold higher compared to 
conventional patch-clamp technique, depending on the platform used [1][2][3][4][10][12]. 
 
1.2.4.1. Automate pipette-based patch-clamping 
 
Attempts to automate conventional (or manual) electrophysiology started in the late 1990s at 
Sophion Biosience with the invention of Apatchi-1 [26]. Since that time, a small number of 
devices have been reported that totally automate manual patch-clamp recordings with glass 
microelectrodes allowing the pipette control, the production of true gigaseals, and execute 
compound application and data acquisition. For measurements on mammalian cells, examples 
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are the Flyscreen (by Flyion) [4][8][12][27], AutoPatch (Xention) [8][28] and RoboPatch 
(Wyeth, later acquired by Pfizer) systems [28][29]. All platforms mentioned above are 
considered as equivalent to manual patch-clamp in terms of quality performance including 
gigaohm seal formation, small access resistance and stability of recordings. Despite the 
advantages of these systems most of them are not commercially available, and the attempts 
for automating conventional glass electrode-based recordings yielded very limited popularity 
due to the low success rate and throughput of measurements [1][5]. 
 
1.2.4.2. Planar-array based approaches 
 
The breakthrough in automated electrophysiology came when planar patch-clamp technology 
without micromanipulation or visual control was launched and become commercially viable 
[5][25]. In this method, by the application of negative pressure cells are moved towards the 
patch-clamp substrate with an array of microapertures for capturing from suspension followed 
by the formation of the seal with the substrate (Figure 1C). Planar arrays replace glass pipette 
electrodes with multi-well configurations either in a plate-based or chip-based format to 
enable higher throughput screening, currently this technology is used in the majority of 
automated systems. Numerous commercially accessible, successful automated systems exist 
on the market which are discussed below [1][3][4][5][7]. 
The IonWorks HT (Essen, later acquired by Molecular Devices) was the first of screening 
platforms that became widely available. This instrument is an integrated system consisting of 
computer-controlled fluid handling, recording electronics and processing tools capable of 
voltage-clamp recordings from up to 384 individual cells per experiment. Cells are positioned 
to a single hole on the planar chip, where an approximately 100 megaohm seal is created. 
Electrical access is achieved by applying permeabilizing agent in the intracellular solution to 
evolve a perforated patch-clamp [1][4][5][7][8][10][12][30]. Next generation systems are the 
IonWorks Quattro and the IonWorks Barracuda with recording concept called ‘population 
patch-clamp’ [4][8][10][12][31][32][33]. In this technique the recorded current is derived 
from an ensemble of cells in contrast to a single cell, which provides close to 100% success 
rate and dramatically reduces well-to-well variability. The IonWorks product family utilize 
plastic recording substrates. On this surface lipophilic compounds can adsorb nonspecifically 
and it also does not support gigaseal recordings. As a result of these phenomenon a consistent 
rightward shift is observed in the compound IC50 values [1][3][4][5][12][34]. Molecular 
Devices has another automated patch-clamp instrument, the PatchXpress. The PatchXpress 
13 
 
uses glass substrates for parallel recordings from 16 wells and enables continuous recordings 
during ligand applications. It supports multiple solution additions and allows the study of both 
voltage-gated and ligand-gated ion channels. In this system, electrical access is achieved by 
rupturing the cell membrane underneath the aperture. It was the first planar-array based 
system which provides gigaohm seal patch-clamp electrophysiology on a chip 
[1][3][4][5][7][8][10][12][35][36]. 
The QPatch was released in 2004 by Sophion Biosience, and reached a quite good market 
acceptance worldwide, due to the properties that compounds affecting both voltage- and 
ligand-gated ion channels can be screened with true gigaseals and acceptable success rates. 
QPatch records from 16 cells simultaneously, utilizing silicon oxide-coated silicon nitride 
structures for high quality recordings. The QPatch was the first planar system designed with 
microfluidics flow capability for rapid solution exchange, allowing the collection of accurate 
pharmacological data [1][3][4][8][12][37]. The following devices were the QPatch HT, 
recording from 48 cells at once and the QPatch HTX using the population patch-clamp 
principle supports a data throughput of 7.000 data points per day [3][4][10][12][37]. 
Nanion Technologies introduced the Port-a-Patch, a miniaturized patch-clamp set-up 
recording from one cell at a time in 2003. The Port-a-Patch makes patch-clamp available to 
non-experts, and is widely used in academic research owing to its great versatility and user-
friendliness [3][4][8][12][38]. The next instrument was the Patchliner (2006), with the 
capability of recording up to eight cells simultaneously, with versatile experimental features 
such as temperature control, current-clamp recordings, external and internal solution 
exchange, fast solution switch times, high success rates with a wide variety of ion channels 
and different cell lines, as well as with primary cells, stem cell-derived cardiomyocytes and 
neurons [4][6][8][12][39][40]. In 2010, Nanion launched the SyncroPatch 96, a screening 
platform recording from 96 cells in parallel. As with all Nanion’s appliances, the SyncroPatch 
96 supports true gigaseals and utilizes a borosilicate glass chips as recording substrates, where 
measurements are possible in different modes including whole-cell, cell-attached and 
perforated-patch configurations. It also has been validated with numerous voltage- and ligand-
gated channels and various cell types. The design supports a data throughput of 6.000 data 
points per day [3][6]. In 2013, Nanion released the SyncroPatch 384/786PE, the first truly 
modular and high-throughput capable automated system with the potential to bridge the gap 
between primary and secondary ion channel drug screening. It offers 384 or 768 recording 
wells for simultaneous measurements, and allows the collection of up to 20.000 data points 
per day, making it the most efficient device on the market for high quality recordings. 
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Two further apparatus, the Dynaflow HT platform from Cellectricon and the IonFlux from 
Fluxion Biosciences utilize a silicone rubber-based (PDMS) microfluidic structure with 
microchannels used for sealing the cells. These systems are unable to perform high quality 
recordings, because of the seals are in the megaohm range. The Dynaflow HT records from 96 
cells simultaneously. The Fluxion’s IonFlux comes in two versions, IonFlux 16 and IonFlux 
HT. The IonFlux HT has 64 individual recording zones per substrate, and could to achieve 
10.000 data points per day. IonFlux systems use the population patch-clamp method. Later the 
Fluxion introduced a new version of the recording cartridge containing one single aperture per 
recording place, for single cell application and also gigaseal recordings [3][33][41]. 
Finally, CytoPatch (from Cytocentrics) is one of the newer robotic platforms, where the 
quartz-microstructured chip design and perfusion system mimics the manual patch-clamp 
technique. Unlike other automated systems, the instrument requires neither high calcium 
buffer to support the sealing process nor fluoride in the intracellular solution to maintain the 
gigaseal and stable whole-cell recording [3][8][42]. 
 
1.3. Aims 
 
Aim of the present work was to investigate the role of automated patch-clamp technique in 
drug research and development and compare it with the conventional cellular 
electrophysiological techniques. The two main scopes of our studies were: 
1. To determine the value of results of screening processes obtained with automated 
patch-clamp methods using cell lines stably expressing ion channels. During this 
phase of work the main goals were to evaluate the usability of the studied automated 
patch-clamp equipment in different screening projects and to analyse the utility of the 
studied system with comparing the effect of the active compounds in cell lines used 
for screening and in native targets measured by the conventional electrophysiological 
methods.     
2. To analyze the value of safety pharmacology data obtained with automated patch-
clamp methods. During this phase of work the main goal was to evaluate the practical 
usability and the biological significance of the results obtained with the studied 
automated patch-clamp equipment in stable cell lines.        
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2. MATERIALS AND METHODS 
 
2.1. Chemicals 
 
All chemicals, which are not specifically indicated, were purchased from Sigma-Aldrich. 
To study the effect of test compounds, a stock solution of test material was prepared in each 
case. The solubilizing agent was dimethyl sulfoxide (DMSO). Aliquots were stored at -20°C. 
Before experiments, stock solutions were further diluted with external solution to give 
appropriate concentrations for the measurements. The final DMSO concentrations in the 
tested samples were 1% or less. 
 
2.2. Ethics statement 
 
All experiments were carried out in compliance with the Guide for the Care and Use of 
Laboratory Animals (USA NIH publication NO 85-23, revised 1996) and conformed to the 
Directive 2010/63/EU of the European Parliament. The protocols have been approved by the 
Ethical Committee for the Protection of Animals in Research of the University of Szeged, 
Szeged, Hungary (approval number: I-74-5-2012) and by the Department of Animal Health 
and Food Control of the Ministry of Agriculture and Rural Development (authority approval 
number XIII/1211/2012). 
 
2.3. Conventional microelectrode technique 
 
New Zealand rabbits of either sex weighing 1-2 kg or adult mongrel dogs (8-14 kg) of either 
sex were used. Rabbits were sacrificed by cervical dislocation after an intravenous injection 
of 400 U/kg heparin, while in case of dogs sedation (xylazine, 1 mg/kg, i.v.) and anaesthesia 
(thiopental, 30 mg/kg, i.v.) were applied. Then the chest was opened, and the heart was 
rapidly removed. The heart was immediately rinsed in oxygenated modified Locke’s solution 
containing (in mM): NaCl 120, KCl 4, CaCl2 1, MgCl2 1, NaHCO3 22 and glucose 11. The 
pH of this solution was set between 7.35 and 7.4 when gassed with the mixture of 95% O2 and 
5% CO2 at 37°C. Isolated muscle preparations obtained from the right ventricle were 
individually mounted in a tissue chamber with the volume of 50 ml. Each preparation was 
initially stimulated through a pair of platinum electrodes in contact with the preparation using 
rectangular current pulses of 2 ms duration. These stimuli were delivered at a constant cycle 
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length of 1000 ms for at least 60 min allowing the preparation to equilibrate before the 
measurements were initiated. Transmembrane potentials were recorded using conventional 
glass microelectrodes, filled with 3 M KCl and having tip resistances of 5-20 MΩ, connected 
to the input of a high impedance electrometer (Experimetria, type 309) which was coupled to 
a dual beam oscilloscope. The resting potential (RP), action potential amplitude (APA), 
maximum upstroke velocity (Vmax) and action potential duration measured at 50% and 90% of 
repolarization (APD50 and APD90, respectively) were off-line determined using a home-made 
software (APES) running on an IBM compatible computer equipped with an ADA 3300 
analogue-to-digital data acquisition board (Real Time Devices) having a maximum sampling 
frequency of 40 kHz. The following types of stimulation were applied in the course of the 
experiments: stimulation with a constant cycle length of 1000 ms; stimulation with different 
constant cycle lengths ranging from 300 to 5000 ms [43][44][45][46][47][48]. 
 
2.4. Manual patch-clamp method 
 
Left ventricular myocytes were enzymatically dissociated from hearts of New Zealand rabbits 
of either sex weighting 1-2 kg using the retrograde perfusion technique [43]. One drop of cell 
suspension was placed in a transparent recording chamber mounted on the stage of an 
inverted microscope. The myocytes were allowed to settle and adhere to the bottom for at 
least 5 minutes before superfusion was initiated with Tyrode solution containing (in mM): 
NaCl 144, NaH2PO4 0.4, KCl 4.0, CaCl2 1.8, MgSO4 0.53, glucose 5.5 and HEPES 5.0 
(pH 7.4, NaOH). Temperature was set to 37°C. Only rod shaped cells with clear cross-
striations were used. Patch-clamp micropipettes were fabricated from borosilicate glass 
capillaries (Harvard Apparatus) using a micropipette puller (Flaming/Brown, type P-97). 
These electrodes had resistances between 1.5 and 2.5 MΩ when filled with pipette solution 
containing (in mM): K-aspartate 100, KCl 40, ATP 5, MgCl2 5, EGTA 4, CaCl2 1.5 and 
HEPES 10 (pH 7.2, KOH). When measuring rapid delayed rectifier potassium currents (IKr), 
1 µM nisoldipine (Bayer AG) was added to the external solution to eliminate L-type Ca2+ 
current (ICa,L). The slow component of the delayed rectifier potassium current (IKs) was 
inhibited by using the selective IKs blocker HMR 1556 (0.5 µM). 
Membrane currents were recorded with Axopatch 200B patch-clamp amplifiers (Molecular 
Devices) using the whole-cell configuration of the patch-clamp technique. After establishing a 
high resistance (1-10 GΩ) seal by gentle suction, the cell membrane beneath the tip of the 
electrode was disrupted by suction or application of short electrical pulses. The series 
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resistance typically ranged from 4 to 8 MΩ before compensation (50-80%). When the series 
resistance was high or substantially increased during the measurement, experiments were 
discarded. Membrane currents were digitized after low-pass filtering at 1 kHz using analog-
to-digital converters (Digidata 1322A and 1440A, Molecular Devices) under software control 
(pClamp 8 and 10, Molecular Devices). The same software was used for off-line analysis 
[45]. IKr was measured using 1000 ms long test pulses between -30 mV and +50 mV. The 
holding potential was -80 mV and during measurements 500 ms long prepulse to -40 mV was 
applied in order to ensure the baseline region. The pulse frequency was 0.05 Hz. The tail 
current at -40 mV after the test pulse was assessed as IKr. The amplitudes of the IKr tail 
currents were determined as the difference between the peak tail current and the baseline. 
 
2.5. Automated patch-clamp experiments 
 
2.5.1. Automated patch-clamp system Patchliner 
 
The automated patch-clamp experiments were executed by using planar patch-clamp 
technology in the whole-cell configuration with a four channel medium throughput fully 
automated patch-clamp platform (Patchliner Quattro, Nanion) with integrated temperature 
control [49]. The software controlling the actions of the Patchliner is the PatchControlHT 
(Nanion) package. Data acquisition and online analysis were performed with an EPC-10 
Quadro patch-clamp amplifier (HEKA), using PatchMaster software (HEKA). 
 
2.5.2. Cells and electrophysiology used for automated patch-clamp measurements 
 
2.5.2.1. Native cells 
 
2.5.2.1.1. Native activated human lymphocytes 
 
Native human lymphocytes were provided by the Department of Biophysics and Cell Biology, 
University of Debrecen. Cells were cultured at 37°C in a humidified atmosphere containing 
5% CO2 in RPMI 1640, supplemented with 10% FBS, 100 mg/l penicillin, 100 mg/l 
streptomycin and 2 mM L-glutamine at 5*10
5
-1*10
6
/ml density for 2-5 days. The culture 
medium also contained 2.5-10 mg/l of phytohemagglutinin A to stimulate proliferation and to 
increase K
+
 channel expression. Before the experiments cultured cells were suspended and 
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centrifuged at 100 g for 2 min, next they were digested with trypsin-EDTA (PAA) for 2 min. 
Trypsin was blocked with the complete culture medium, then cells were centrifuged at 100 g 
for 2 min and washed in PBS (Life Technologies) and centrifuged again. Finally, cells were 
resuspended in 1-1.5 ml extracellular solution for patch-clamp measurements. 
The extracellular solution consisted of (in mM): NaCl 145, KCl 5, MgCl2 1, CaCl2 2.5, 
glucose 5.5 and HEPES 10 (pH 7.35, NaOH). The internal solution consisted of (in mM) 
KF 112, MgCl2 2, CaCl2 1, HEPES 8 and EGTA 11 (pH 7.22, KOH). Kv1.3 currents were 
measured in human peripheral T lymphocytes at room temperature. The currents were evoked 
by 15 ms long pulses to 50 mV from a resting potential of -120 mV in every 15 s. [50]. 
Experiments started in extracellular solution. After the control phase, the increasing 
concentrations of the test compound were added, each for approximately 5 minutes, then a 
wash-out step terminated the measurements. 
 
2.5.2.2. Stable transfected cell lines 
 
Automated patch-clamp experiments were carried out on suspension of stable transfected cell 
lines. Suspension of cells for measurements was derived from running cell culture. Cells were 
maintained in incubator at 37°C, in 5% CO2. Before experiments, cells were washed twice 
with PBS (Life Technologies) and then detached with trypsin-EDTA (PAA) for 30-180 s 
depending on cell line. Trypsin was blocked with serum containing complete culture medium. 
The cell suspension was next centrifuged (2 min, 100 g), resuspended in serum free base 
medium at a final density of 1*10
6
-5*10
6
 cells/ml, and kept in the cell hotel of the Patchliner. 
Cells were recovered after 15-30 min and remained suitable for automated patch-clamp 
recordings for up to 4 hours. 
Stock of extra- and intracellular solutions were made for automated patch-clamp recordings 
on stable transfected cell lines. All solutions were sterile filtered. Aliquots were stored at 
-20°C and warmed up to room temperature before use.  
 
2.5.2.2.1. HEK-GABA cell line 
 
Experiments were carried out at room temperature, on HEK293 cells stably expressing the 
GABAA receptor (α5β2γ2 subunit composition). The GABAA cell line was provided by EGIS 
and all results related to this cell line in this thesis are shown with the permission of EGIS. 
Cells were cultured in DMEM (Life Technologies) medium supplemented with 10% FBS, 
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3 mg/l puromycin, 600 mg/l G418 (Life Technologies), 200 µg/ml zeocin (Life Technologies) 
and 10 mM KCl. 
The following solutions were used for automated patch-clamp recordings (compositions in 
mM): external solution: NaCl 140, KCl 4, glucose-monohydrate 5, MgCl2 1, CaCl2 3 and 
HEPES 10 (pH 7.4, NaOH); internal solution: KCl 50, NaCl 10, KF 60, EGTA 20 and 
HEPES 10 (pH 7.2, KOH). During measurements cells were clamped to a holding potential of 
-50 mV. For GABA ion channel assay, the stacked application was used. In this method, the 
extracellular solution was aspirated to the pipette, directly followed by a plug of compound. 
In this way, the cell was exposed to GABA for accurately 5 s, and then 3 minutes long 
washout step occurred. To investigate test compounds, cells were stimulated with control 
applications of GABA. Control applications were followed by 3 min pre-incubation of test 
compound. Then the co-applications of compound and GABA were established for 5 s, and 
the washout step terminated the protocol cycle. This cycle was repeated with the increasing 
concentrations of the investigated drug. 
 
2.5.2.2.2. HEK-HCN1 and HEK-HCN4 cell lines 
 
Experiments were performed at room temperature, on HEK293 cell line stably expressing the 
HCN1 or the HCN4 K
+
 channels. Cell lines were provided by the University of Florence. 
Cells were maintained in DMEM (Life Technologies) medium contained 10% FBS, 
200 µg/ml G418 (Life Technologies), 100 U/ml penicillin and 100 µg/ml streptomycin. 
The following solutions were used for patch-clamp measurements (compositions in mM): 
external solution: NaCl 140, KCl 4, glucose-monohydrate 5, MgCl2 1, CaCl2 3 and HEPES 10 
(pH 7.4, NaOH); high K
+
 external solution: NaCl 135, KCl 25, MgCl2 1, CaCl2 3 and 
HEPES 10 (pH 7.4, NaOH); K
+
-free external solution: NaCl 160, MgCl2 1, CaCl2 3 and 
HEPES 10 (pH 7.4, NaOH); internal solution: KCl 50, NaCl 10, KF 60, EGTA 20 and 
HEPES 10 (pH 7.2, KOH). To measure HCN current, the cells were hyperpolarized to 
-100 mV for 4 s, then they were repolarized to 5 mV for 500 ms. The resting potential was 
-35 mV, the pulse frequency was 0.1 Hz. Gigaseal and whole-cell created in the normal 
external solution (4 mM K
+
). Then high K
+
 external solution was used to amplify the current. 
After the control period, K
+
-free external solution was applied. Finally the test compounds 
dissolved in high K
+
 external solution were added to the cells for 5 min. The data were 
corrected with the current values measured in the K
+
-free external solution, which served as 
the baseline. 
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2.5.2.2.3. HEK-GIRK1/4 cell line 
 
Experiments were executed at room or physiological (37°C) temperature, on HEK293 cells 
stably expressing the GIRK1/4 (Kir3.1/3.4) K
+
 channels. The cell line derived from UCL 
Business PLC. Cells were breeded in MEM medium (PAA) supplemented with 10% FBS 
(PAA) and 182 μg/ml zeocin (Life Technologies). 
The undermentioned solutions were used during patch-clamp recordings (compositions in 
mM): external solution: NaCl 140, KCl 4, glucose-monohydrate 5, MgCl2 1, CaCl2 3 and 
HEPES 10 (pH 7.4, NaOH); high K
+
 external solution: NaCl 135, KCl 25, MgCl2 1, CaCl2 3 
and HEPES 10 (pH 7.4, NaOH); K
+
-free external solution: NaCl 160, MgCl2 1, CaCl2 3 and 
HEPES 10 (pH 7.4, NaOH); internal solution: K-gluconate 40, NaCl 20, KF 60, EGTA 20 
and HEPES 10 (pH 7.2, KOH), supplemented with 0.9 mM GTPγS before the experiments to 
induce channel activation. The voltage protocol for GIRK ion channel assays started with a 
depolarizing voltage step to 60 mV for 100 ms before a 500 ms hyperpolarizing ramp to 
-140 mV was applied. The membrane potential then remained at -140 mV for 100 ms before 
returning to the holding potential of -40 mV. The inward currents were calculated from the 
-140 mV segment. The pulse frequency was 0.1 Hz. Recording started in the normal external 
solution (4mM K
+
). High K
+
 external solution was then applied to increase the current 
amplitude. After a 3 minutes control period, the test compounds were added to the cells in 
increasing concentrations, each for approximately 3 minutes and then K
+
-free external 
solution was applied. The data were corrected with the current values measured in the K
+
-free 
external solution, which served as the baseline [51][52]. 
 
2.5.2.2.4. CHO-Kv1.4 cell line 
 
Experiments were carried out at room temperature, on CHO-K1 cell line stably expressing the 
Kv1.4 K
+
 channel. The cells were purchased from UCL Business PLC. Cells were cultured in 
F12 (Life Technologies) medium contained 10% FBS (PAA) and 500 µg/ml hygromycin 
(PAA). 
The following solutions were used for patch-clamp recordings (compositions in mM): 
external solution: NaCl 140, KCl 4, glucose-monohydrate 5, MgCl2 1, CaCl2 3 and HEPES 10 
(pH 7.4, NaOH); internal solution: KCl 50, NaCl 10, KF 60, EGTA 20 and HEPES 10 
(pH 7.2, KOH). To study the Kv1.4 channels, we applied 1 s long 50 mV voltage steps. The 
resting potential was -80 mV; the time between depolarizing pulses was approximately 
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10 seconds. Peak current was corrected the current value of the steady state phase of the 
voltage step. After the control phase of measurements, the increasing concentrations of the 
test compound were added, each for approximately 3 minutes, and a wash-out step terminated 
the protocol. 
 
2.5.2.2.5. HEK-hERG cell line 
 
Measurements were performed at room or physiological (37°C) temperature, on HEK293 
cells stably expressing the hERG (Kv11.1) K
+
 channel. The cell line originated from Cell 
Culture Service. Cells were maintained in IMDM (PAA) medium supplemented with 10% 
FBS (PAA), 2 mM L-glutamine (Life Technologies), 1 mM Na-piruvate (PAA) and 
500 µg/ml G418 (PAA). 
The following solutions were used during patch-clamp experiments (compositions in mM): 
external solution: NaCl 140, KCl 4, glucose-monohydrate 5, MgCl2 1, CaCl2 3 and HEPES 10 
(pH 7.4, NaOH); internal solution: KCl 50, NaCl 10, KF 60, EGTA 20 and HEPES 10 
(pH 7.2, KOH). The voltage protocol for hERG ion channel started with a short (100 ms) 
-40 mV step, as a reference. A 20 mV depolarizing step was applied for 3 seconds, and then 
the test potential was -40 mV for 1 s to evoke outward tail current. Holding potential was 
-80 mV; pulse frequency was 0.1 Hz. The peak tail current was corrected the leak current 
defined during the first period to -40 mV. Experiment started in external solution. After the 
control period, the increasing concentrations of the test compound were applied, each for 
approximately 3 minutes, then a wash-out step completed the protocol [44][51]. 
 
2.6. Statistics 
 
Data are expressed as arithmetic mean ± SEM values. Results were compared using Student’s 
t-tests for paired data. Differences were considered significant when P value was less than 
0.05. 
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3. RESULTS 
 
3.1. Evaluation and characterization of different cell lines with Patchliner  
 
3.1.1. Evaluation and characterization of Kv1.3 K
+
 channel in native activated human 
lymphocytes 
 
Kv1.3 is a voltage-gated K
+
 channel, which is the main ion channel of human T lymphocytes 
and plays a crucial role in antigen-dependent activation and proliferation. Characterization of 
Kv1.3 channel was performed using the non-selective K
+
 channel blocker 
tetraethylammonium (TEA) and two selective blockers of the channel, anuroctoxin (AnTx) 
and margatoxin (MgTx). TEA reduced the Kv1.3 current in dose-dependent manner showing 
a 28.14 ± 3.11 mM IC50 value (Figure 2). 
 
 
Figure 2. Concentration-dependent inhibitory effect of TEA on Kv1.3 current. Panel A shows representative 
Kv1.3 current curves obtained from lymphocyte treated with different concentrations of TEA. Panel B shows the 
dose-response curves of TEA. IC50 was 28.14 ± 3.11 mM (n = 6). 
 
Two selective Kv1.3 blocker peptid toxins originated from scorpion poison were also 
investigated. Both anuroctoxin and margatoxin inhibited the current in concentration-
dependent manner. The IC50 values of both toxins found to be were very low: 
25.35 ± 1.64 nM (AnTx) and 68.59 ± 16.68 pM (MgTx) (Figure 3). 
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Figure 3. Concentration-dependent blocking effects of scorpion toxins on Kv1.3 current. Panel A and B present 
typical current curves recorded during application of increasing concentrations of AnTx and MgTx. Panel C shows 
the dose-response curves of the examined toxins. AnTx and MgTx were extremely effective with 
IC50 = 25.35 ± 1.64 nM (n = 5) and IC50 = 68.59 ± 16.68 pM (n = 5), respectively. 
 
3.1.2. Evaluation of GABA receptors  
 
The GABA receptor family is the major class of inhibitory chloride ion channels in central 
nervous system. This channel is known as a ligand-gated ion channel on which gamma-
aminobutyric acid (GABA) acts as the activator ligand of the channel. GABAA channels were 
investigated using a stacked application for rapid administration of agonists to cells, in order 
to study concentration response relations. Figure 4 shows dose-response curve obtained with 
the application of 1, 3, 10, 30, 100 and 300 µM of GABA. Peak current amplitudes were 
normalized to the current activated by the maximum concentration of GABA (300 µM is the 
saturating concentration based on preliminary experiments, data are not shown). The EC50 
was determined to 32.20 ± 1.85 µM from the Hill plot. 
Potential desensitization of the channel by GABA was also tested. GABA in 10 µM 
concentration was applied 10-15 times on the investigated cells during these experiments. 
Desensitization was not observed under these circumstances. 
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Figure 4. Effect of GABA on whole-cell current. Panel A depicted sample current curves evoked by different 
concentrations of GABA. Panel B shows the dose-response relationship of GABA. The EC50 value was 
determined to 32.20 ± 1.85 µM (n = 5) by plotting the normalized peak current amplitudes against concentration. 
 
The effect of the GABAA channel antagonist bicuculline was investigated on GABAA current. 
In these experiments, shown in Figure 5, cells were stimulated with control applications of 
10 µM GABA. Control applications were followed by the increasing concentrations of 
bicuculline (100 nM, 1 µM, 10 µM) co-applied with GABA (10 µM). The values for the peak 
amplitudes were normalized against the control. The estimated IC50 value was 
371.06 ± 3.43 nM. 
 
 
Figure 5. Investigation of bicuculline block on GABAA current. Panel A shows the application of control (10 µM 
GABA) followed by co-application of 10 µM GABA with increasing concentrations of bicuculline. Panel B shows 
the concentration-response curve of bicuculline. IC50 was estimated at 371.06 ± 3.43 nM (n = 3). 
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3.1.3. Evaluation of HCN ion channels 
 
HCN channels are the molecular determinants of the pacemaker or funny current (If) in the 
heart. Cells of the investigated cell lines (HCN1 and HCN4) showed very small HCN currents 
under physiological circumstances (e.g. 4 mM K
+
). These weak currents did not allow to 
perform trustable experiments with automated systems, therefore the effect of higher 
extracellular K
+
 concentrations on the currents was investigated (Figure 6).  
 
 
Figure 6. Effects of extracellular K+ concentrations on HCN current. Panel A presents representative HCN1, 
panel B shows typical HCN4 current sweeps evoked by 0, 4, 10, 25, 50 and 75 mM of external K+. 
 
 
Figure 7. Inhibitory effects of 10 μM ivabradine on HCN channels. Panel A shows representative HCN1, panel B 
shows typical HCN4 current curves obtained from cells treated with 10 μM ivabradine. K+-free external solution 
served as baseline. Ivabradine (10 μM) reduced HCN1 and HCN4 currents by 64.52 ± 5.36% (n=5) and 
63.79 ± 1.07% (n=6), respectively. 
 
Both HCN1 and HCN4 currents have shown an obvious dependency on external K
+
 
concentration in the 0-75 mM range, although there was a remarkable difference in their 
activation kinetics. Since the elevated K
+
 levels increased HCN currents widely, external 
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solution containing 25 mM K
+
 was chosen for use in our experiments. This level of K
+
 was 
found to be the lowest one providing a current on which changes can be safely detected. 
The blocking action of ivabradine on HCN1 and HCN4 channels expressed in HEK cells was 
also investigated. Ivabradine reduced both currents in 10 μM concentration by 64.52 ± 5.36% 
(n = 5) and 63.79 ± 1.07% (n = 6), respectively (Figure 7).  
 
3.1.4. Evaluation of GIRK potassium channels 
 
GIRK1/4 potassium channels are selectively expressed in the cardiac atrium, and responsible 
for K
+
-fluxes and membrane repolarisation and/or hyperpolarisation. To find the ideal 
formulation of extracellular solution, different external K
+
 concentrations were tested. GIRK 
current obtained in HEK-GIRK cells showed a definite potassium dependency in the 
investigated concentration range (0-75 mM K
+
) (Figure 8). 
 
 
Figure 8. Effects of extracellular K+ concentrations on GIRK current. Illustration depicted sample whole-cell 
currents evoked by 0, 4, 10, 25, 50 and 75 mM of external K+ on the GIRK channel. 
 
External solution containing 25 mM K
+
 was chosen for use in our GIRK experiments, since 
this was found to be the lowest K
+
 level providing a current on which changes can be safely 
detected. 
Six compounds were studied on HEK-GIRK cells. These experiments were performed at 
room temperature and results grounded for the screening project performed (see Section 3.2.) 
on the same cell line also at room temperature. The IC50 of chloroquine, desipramine, 
JTV-519, NIP-142, propafenone and quinidine were 463.70 ± 34.61 nM, 1.47 ± 0.17 μM, 
814.24 ± 109.34 nM, 175.75 ± 8.59 nM, 372.99 ± 27.69 nM and 5.04 ± 0.62 μM, respectively 
(Figure 9). 
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Figure 9. Dose-response curves of six reference agents on GIRK current at room temperature. The IC50 of 
chloroquine, desipramine, JTV-519, NIP-142, propafenone and quinidine were 463.70 ± 34.61 nM, 1.47 ± 0.17 
μM, 814.24 ± 109.34 nM, 175.75 ± 8.59 nM, 372.99 ± 27.69 nM and 5.04 ± 0.62 μM, respectively (n = 5-8). 
 
 
Figure 10. Concentration-dependent inhibitory effects of amiodarone and desethylamiodarone on GIRK current 
at 37°C. Panels A and B shows representative GIRK current sweeps obtained from cells treated with increasing 
concentrations of amiodarone and DEA. K+-free external solution served as baseline. Panel C presents the dose-
response curves of amiodarone (IC50 = 1.77 ± 0.18 μM, n = 5) and DEA (IC50 = 1.82 ± 0.15 μM, n = 5). 
 
Effect of the antiarrhythmic drug amiodarone and its main metabolite formed during chronic 
treatment (desethylamiodarone, DEA) was also investigated on HEK-GIRK cells. These 
studies were performed as parts of the cardiac electrophysiological investigation of these 
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compounds and were performed at 37°C. The IC50 values determined by the Patchliner were 
nearly identical (1.77 ± 0.18 and 1.82 ± 0.15 μM, respectively, see on Figure 10). 
 
3.1.5. Evaluation of Kv1.4 potassium channels  
 
Kv1.4 is a voltage-gated potassium channel, which opens on membrane depolarization and 
inactivate rapidly. Kv1.4 channel underlie the cardiac transient outward potassium current 
(Ito) in cardiac muscle. The blocking effects of chromanol 293B and 4-aminopyridine on 
Kv1.4 ion channel were investigated at room temperature. Estimated IC50 values of these 
compounds found to be 85.69 ± 8.38 μM and 791.33 ± 26.84 μM, respectively (Figure 11). 
 
 
Figure 11. Concentration-dependent blocking effects of chromanol 293B and 4-aminopyridine on Kv1.4 currents. 
Panel A and B present representative current curves recorded during application of increasing concentrations of 
chromanol 293B and 4-aminopyridine. Panel C shows the dose-response curves of the reference compounds. 
The estimated IC50 values were 85.69 ± 8.38 μM (n = 4) and 791.33 ± 26.84 μM (n = 4), respectively. 
 
3.1.6. Evaluation of hERG potassium channels 
 
hERG channel is a K
+
 selective voltage-gated ion channel, belonging to the Kv channel 
family, also referred to as Kv11.1. hERG channels mediate the rapid delayed rectifier K
+
 
current (IKr) in ventricular myocytes. Two compounds, dofetilide and sotalol were tested in 
hERG assay with automated patch-clamp system. Results are shown in details in Section 
3.3.1. 
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3.2. Screening projects: Investigation of ion channel modulator capability of compounds 
with automated patch-clamp equipment  
 
The characterized cell lines were used in screening and safety pharmacology projects 
performed with the Patchliner. Screening projects involved Kv1.3, GABA, GIRK, Kv1.4 and 
hERG cell lines. All screening projects were carried out at room temperature. Screen results 
obtained with Kv1.3 and GABA cell lines are not shown in this section due to the intellectual 
property policy of our industrial research partners.        
 
3.2.1. Screening of preselected chemical libraries on GIRK channel 
 
In order to find agents for the treatment of atrial fibrillation, screening of preselected chemical 
libraries was performed on GIRK channel expressing cell line. Selective GIRK blocking 
agents found to be effective against atrial fibrillation in previous studies. During our screening 
project a set of 868 compounds originated from the Department of Organic Chemistry, 
Semmelweis University, Budapest, and the Institute of Pharmaceutical Chemistry, University 
of Szeged was tested. All screened compounds were chosen for GIRK studies during a 
selection process where the chemical structure of the compounds was compared to the known 
antagonists of GIRK channel. Approximately the 10% of the revised chemical libraries were 
selected as possible potent structures and were investigated in automated patch-clamp studies. 
Compounds were screened in two concentrations (1 and 10 μM) on at least 2 cells.  
Approximately 13% of the investigated compounds showed a notable (i.e. at least 50% 
decrease in the GIRK current at 10 μM concentration) blocking effect. Compounds were 
ranked according to their GIRK inhibitory effect. Eleven compounds were chosen from the 
group of most effective molecules upon their blocking effect and chemical structure. The 
dose-response curves of these compounds were determined in detailed experiments where 
effect of the chosen compounds was tested in 6 concentrations on at least 6 cells. Dose-
response curves and IC50 values of these compounds are shown in Figure 12.  
Substrates were chosen for selectivity studies by the more precise results of these later 
studies: hERG inhibitory properties of 4 compounds with the most intense GIRK blocking 
effect (Ryt-143, Ryt-144, Ryt-230 and Ryt-243 – all having IC50 values under 0.5 μM) were 
investigated on HEK-hERG cells in 6 concentrations. These dose-response curves were 
derived from experimental results obtained at least from 5 cells. GIRK and hERG dose-
response curves of these listed compounds are shown in Figure 13.  
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Figure 12. Dose-response curves of eleven compounds which were selected after GIRK screening project of 
chemical libraries upon their blocking effect and chemical structure. IC50 values were 100.14 ± 5.10 nM for 
Ryt-243, 281.29 ± 9.48 nM for Ryt-144, 335.30 ± 23.81 nM for Ryt-143, 495.43 ± 15.90 nM for Ryt-230, 
936.31 ± 118.30 nM for Ryt-832, 968.60 ± 94.44 nM for Ryt-120, 1.62 ± 0.20 μM for Ryt-879, 2.37 ± 0.38 μM for 
Ryt-830, 3.91 ± 0.12 μM for Ryt-612, 4.56 ± 0.28 μM for Ryt-150 and 4.56 ± 0.34 μM for Ryt-640 (n = 6-9). 
 
One out of the 4 chosen compounds showed similar blocking activity on both GIRK and 
hERG channels: IC50 values of Ryt-243 were 100.14 ± 5.10 nM and 47.56 ± 5.31 nM, 
respectively. The other 3 compounds (Ryt-143, Ryt-144 and Ryt-230) showed an at least 10 
times higher blocking activity on GIRK channels compared to the results obtained on hERG 
channel. As hERG blocking effect can be even useful in antiarrhythmic treatment Ryt-243 
was subjected to further investigation: despite of its hERG blocking effect the compound 
lengthened the action potential in rabbit ventricular muscle neither in 5 µM nor in 10 µM 
concentrations (Figure 14). This discrepancy needs further examinations. Ryt-243 was also 
studied in dog model of chronic atrial fibrillation. The compound had a strong antiarrhythmic 
effect in this investigational set-up: the incidence of atrial fibrillation was reduced by 65-70% 
by both 0.3 mg/kg and 1 mg/kg doses. Based on these antiarrhythmic results a patent was 
filed in which anti-atrial fibrillation effects of Ryt-243 are chartered. Compounds showing 
GIRK-selectivity (Ryt-143, Ryt-144 and Ryt-230) are also subjected to further investigation 
including antiarrhythmic effect evaluation and structure-effect analysis.  
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Figure 13. GIRK and hERG dose-response curves of 4 compounds with the most intense GIRK blocking effect. 
Panel A shows the blocking activity of Ryt-243 on GIRK and hERG channels. The inhibitory properties were 
similar with IC50 values 100.14 ± 5.10 nM and 47.56 ± 5.31 nM, respectively. Panel B, C and D depicted the 
concentration-response relationship of Ryt-144, Ryt-143 and Ryt-230, respectively, on GIRK and hERG channels. 
These three compounds show severe GIRK-selectivity. IC50 values on GIRK and hERG channels were 
281.29 ± 9.48 nM and 2.91 ± 0.29 μM for Ryt-144, 335.30 ± 23.81 nM and 8.05 ± 0.89 μM for Ryt-143, 
495.43 ± 15.90 nM and 9.16 ± 1.30 μM for Ryt-230 (n = 5-7). 
 
 
Figure 14. Effects of Ryt-243 on action potential waveform of rabbit ventricular muscle at stimulation cycle length 
of 1000 ms. Ryt-243 prolonged the action potential neither in 5 µM nor in 10 µM concentrations. 
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3.2.2. Screening of different substrates originated from plants on GIRK channel 
 
3.2.2.1. Screening of natural plant compounds on GIRK channel 
 
Compounds originated from natural sources were also investigated in our GIRK screen 
project. During this phase of screening project a set of 281 natural plant compounds 
originated from the Department of Pharmacognosy, University of Szeged was tested [51]. 
These molecules were chosen randomly and were not selected as the expected high hit rate of 
the natural compounds. Compounds were screened also in two concentrations (1 and 10 μM) 
on at least 2 cells. 
 
 
Table 1. Blocking effects of the 26 most effective natural compounds in 10 μM concentration on GIRK (green), 
Kv1.4 (blue) and hERG (red) ion channels (n = 2-3).  
 
Ryt-1197 90 ± 1 18 ± 12 45 ± 6
Ryt-1196 88 ± 1 21 ± 8 31 ± 6
Ryt-1189 87 ± 5 14 ± 1 39 ± 1
Ryt-1194 86 ± 1 5 ± 7 21 ± 11
Ryt-1190 84 ± 7 28 ± 2 31 ± 1
Ryt-963 83 ± 11 38 ± 11 22 ± 6
Ryt-1009 82 ± 1 89 ± 8 15 ± 4
Ryt-1010 80 ± 2 34 ± 7 29 ± 1
Ryt-1007 78 ± 4 39 ± 6 13 ± 4
Ryt-1195 77 ± 9 28 ± 4 15 ± 3
Ryt-945 77 ± 6 21 ± 2 98 ± 6
Ryt-1187 76 ± 2 0 ± 10 14 ± 9
Ryt-962 70 ± 3 28 ± 5 14 ± 5
Ryt-1083 67 ± 5 11 ± 3 70 ± 5
Ryt-964 67 ± 1 34 ± 7 1 ± 9
Ryt-1183 67 ± 9 2 ± 4 17 ± 12
Ryt-1103 64 ± 6 13 ± 8 5 ± 4
Ryt-1161 63 ± 2 1 ± 8 43 ± 1
Ryt-944 61 ± 6 16 ± 7 98 ± 2
Ryt-985 58 ± 7 28 ± 2 47 ± 7
Ryt-965 57 ± 1 16 ± 7 0 ± 2
Ryt-1193 57 ± 11 9 ± 10 6 ± 7
Ryt-1084 56 ± 8 27 ± 2 35 ± 3
Ryt-947 55 ± 1 7 ± 7 73 ± 11
Ryt-1186 55 ± 8 10 ± 1 29 ± 4
Ryt-958 50 ± 2 14 ± 12 25 ± 5
GIRK Kv1.4
Inhibition (%) in 10 μM ± SEM
hERG
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Approximately 9% of the investigated natural compounds showed a notable (i.e. at least 50% 
decrease in the GIRK current at 10 μM concentration) blocking effect. 
The 26 most effective molecules were selected for further evaluation following the primary 
screen. These compounds were also tested on Kv1.4 and hERG cell lines and selectivity of 
their GIRK blocking effect was evaluated with these experiments. Blocking effects of these 
agents in 10 μM concentration on the investigated 3 different ion channels are shown in 
Table 1. 
Six natural plant compounds (Ryt-963, Ryt-964, Ryt-1009, Ryt-1103, Ryt-1187 and 
Ryt-1194) were chosen from the group of most effective ones upon their blocking effects and 
chemical structure. The dose-response curves of these 6 molecules were determined in 
detailed experiments where effect of the chosen compounds on GIRK current was tested in 
4-5 concentrations on at least 5 cells. Dose-response curves and IC50 values of these 
compounds are shown in Figure 15. 
 
 
Figure 15. Dose-response curves of six agents which were selected after GIRK screening project of natural plant 
compounds upon their blocking effect, chemical structure and selectivity. IC50 values were 524.25 ± 35.87 nM for 
Ryt-963, 2.25 ± 0.33 μM for Ryt-1009, 3.66 ± 0.30 μM for Ryt-964, 5.33 ± 0.23 μM for Ryt-1194, 9.68 ± 0.27 μM 
for Ryt-1187 and 12.20 ± 0.31 μM for Ryt-1103 (n = 5-7). 
 
3.2.2.2. Screening of plant extracts on GIRK channel  
 
Testing a new way of tracing biologically active compounds extracts of Polygonum persicaria 
were also investigated in our GIRK screen system, with the aim to identify natural sources of 
promising ion channel blocking compounds [52]. For this purpose hexane, chloroform, 
Concentration (nM)
10 100 1000 10000 100000
In
h
ib
it
io
n
 (
%
)
0
20
40
60
80
100 Ryt-963
IC50 = 524.25 nM
Ryt-1009
IC50 = 2.25 M
Ryt-964
IC50 = 3.66 M
Ryt-1194
IC50 = 5.33 M
Ryt-1187
IC50 = 9.68 M
Ryt-1103
IC50 = 12.20 M
34 
 
methanol and aqueous extracts were prepared from the dried whole plant. Extracts of different 
polarity were investigated at two concentrations (0.01 mg/l and 0.1 mg/l). The chloroform 
extract exhibited considerable GIRK channel inhibitory activity. This extract was fractionated 
by vacuum liquid chromatography on RP-silica gel resulting six fractions (fractions 1-6), 
which were also evaluated for GIRK modulation activity. The most active fractions (fraction 
4 and 5) were subjected then to RP-HPLC, affording the isolation of the main compounds 1-4 
in pure form. The eluates containing the mixture of other (minor) compounds were also 
collected during the HPLC chromatography. Both the isolated compounds (at 1 and 10 μM 
concentration) and the HPLC eluates of the highly active fractions of the chloroform extract 
- presumably containing unidentified minor compounds - were involved in the GIRK channel 
inhibitory assay. Table 2 shows GIRK channel blocking effects of Polygonum persicaria 
extracts, fractions and isolated compounds.  
 
 
Table 2. GIRK channel inhibitory activity of Polygonum persicaria extracts (blue), fractions of chloroform extract 
(green), isolated compounds of fraction 4-5 (orange) and fraction 4-5 eluate (red) (n = 3-5). 
 
Interestingly, either separated or combined application of the isolated main compounds of the 
active fractions (compound 1-4) possess only very moderate activity on GIRK channel, while 
the HPLC eluates of fraction 4 and 5 containing a mixture of minor compounds revealed to be 
Extract hexane 7 ± 2 24 ± 8
Extract chloroform 23 ± 4 76 ± 4
Extract methanol 8 ± 1 16 ± 8
Extract H2O 19 ± 3 25 ± 2
Fraction 1 14 ± 3 30 ± 4
Fraction 2 12 ± 6 19 ± 7
Fraction 3 16 ± 5 25 ± 3
Fraction 4 13 ± 5 60 ± 5
Fraction 5 26 ± 6 68 ± 6
Fraction 6 8 ± 3 23 ± 6
Compound 1 12 ± 3 13 ± 5
Compound 2 11 ± 3 19 ± 5
Compound 3 16 ± 6 22 ± 6
Compound 4 13 ± 2 20 ± 2
Compound 1+2+3+4 8 ± 4 22 ± 10
Fraction 4 eluate 30 ± 1 63 ± 5
Fraction 5 eluate 34 ± 3 62 ± 2
0.01 mg/ml 0.1 mg/ml
1 μM 10 μM
Inhibition (%) ± SEM
0.01 mg/ml 0.1 mg/ml
0.01 mg/ml 0.1 mg/ml
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active, indicate the presence of electrophysiologically active agents among the minor 
compounds. Further studies are on the way in order to identify the minor compounds 
responsible for the GIRK channel blocking effect. Nevertheless our studies confirm the 
usability of the applied method of tracing active compounds upon their biological activity.   
 
3.3. Safety pharmacology studies 
 
3.3.1. Assessment of hERG assay performed with automated patch-clamp system in the 
safety evaluation of investigational compounds 
 
 
Figure 16. Effect of dofetilide on hERG and IKr current and on action potential waveform. Panel A shows example 
traces for hERG mediated currents obtained from HEK-hERG cell treated with 10 nM dofetilide at room 
temperature. Panel B depicted the effect of 10 nM dofetilide on hERG current at 37°C. Dofetilide inhibited the 
peak tail currents on these temperatures in similar rate but with different kinetics. Panel C shows sample IKr 
current sweeps obtained from rabbit ventricular muscle cells treated with 10 nM dofetilide. Panel D shows the 
dose-response curves of dofetilide derived from hERG on room temperature and on 37°C (n = 5) and IKr (n = 2-6) 
experiments. The IC50 values were in good correlation with a value of 8.41 ± 0.19 nM, 7.29 ± 0.16 nM and 
13.02 ± 2.56 nM, respectively. Panel E presented the effects of 13 nM dofetilide on action potential waveform of 
rabbit ventricular muscle at stimulation cycle length of 1000 ms. 
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Two compounds (dofetilide and sotalol) were tested in hERG assay both at room temperature 
and at 37°C with automated patch-clamp system. The IC50 values of dofetilide were very 
similar (8.41 ± 0.19 nM at room temperature and 7.29 ± 0.16 nM at 37°C). Sotalol displayed 
different properties at room temperature versus physiological temperature (37°C). Sotalol 
blocked hERG channels at room temperature with an IC50 of 773.74 ± 9.28 μM. However, at 
37°C sotalol was more potent (IC50 = 342.84 ± 24.82 μM). 
 
 
Figure 17. Effect of sotalol on hERG and IKr current and on action potential waveform. Panel A shows 
representative hERG current curves obtained from HEK-hERG cell treated with 100 μM sotalol at room 
temperature. Panel B displays the effect of 100 μM sotalol on hERG current at 37°C. Sotalol had little effect on 
room temperature, and also mild but somewhat stronger blocking effect on 37°C. Panel C shows representative 
IKr current curves obtained from rabbit ventricular muscle cells treated with 100 μM sotalol. The effect was more 
remarkable than hERG current. Panel D shows the concentration-response curves of sotalol obtained from hERG 
at room temperature and at 37°C (n = 5-6) and IKr (n = 2-6) measurements. The IC50 values are drastically 
different with a value of 773.74 ± 9.28 μM, 342.84 ± 24.82 μM and 51.60 ± 9.82 μM, respectively. Panel E shows 
the effects of 52 μM sotalol on action potential waveform of rabbit ventricular muscle at stimulation cycle length of 
1000 ms. 
 
To evaluate the prognostic value of hERG assay these compounds were subjected for further 
investigations. The IKr current blocking capability of the compounds was tested on rabbit 
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ventricular muscle with manual patch-clamp method. The IC50 values of dofetilide and sotalol 
were 13.02 ± 2.56 nM and 51.60 ± 9.82 μM, respectively. IC50 values obtained in hERG and 
IKr assays showed a good correlation in case of dofetilide while IC50 value obtained from IKr 
measurements was lower approximately 7 times in case of sotalol. The results of both 
automated and manual patch-clamp experiments are shown in Figure 16 and Figure 17. 
To study the safety pharmacology consequences of the hERG and IKr inhibitory effect of 
dofetilide and sotalol the effect of these compounds on action potential configuration were 
studied in rabbit right ventricular muscle preparations. In these investigations, the IC50 values 
obtained from IKr experiments were applied. Both agents significantly lenghtened the action 
potential duration at stimulation cycle length of 1000 ms. The prolongation of APD90 was 
47.8 ± 12.9 % (n = 7) in case of 13 nM dofetilide while 52 μM sotalol extended the action 
potential duration with 56.0 ± 4.6 % (n = 5). The results are presented in Figure 16, Figure 17 
and Table 3.  
 
 
Table 3. The electrophysiological effects of 13 nM dofetilide and 52 μM sotalol in rabbit ventricular muscle 
preparations at basic cycle length of 1000 ms. RP, resting potential; APA, action potential amplitude; Vmax, 
maximum rate of depolarization; APD90 and APD50, action potential durations at 50% and 90% of repolarization. 
Results are mean ± SEM, n = 5-7. 
 
3.3.2. Effects of Chelidonium majus extracts and major alkaloids on hERG ion channel 
and on dog cardiac action potential 
 
Chelidonium majus or greater celandine is spread throughout the world, and it is an important 
plant of the modern phytotherapy, used not only externally, but also internally. Although 
C. majus contains alkaloids with remarkable physiological effect, safety pharmacology 
properties of this plant are not widely clarified. Therefore, effects of C. majus herb extracts 
and alkaloids on hERG K
+
 current as well as on cardiac action potential were studied [44]. 
 
 
 
 
RP (mV) APA (mV) Vmax (V/s) APD90 (ms) APD50 (ms)
Control -88.3 ± 0.3 109.0 ± 2.4 182.1 ± 12.4 190.5 ±  14.1 154.7 ±  15.1
Dofetilide 13 nM -87.6 ± 0.8 109.3 ± 3.5 187.0 ± 15.9 285.9 ± 40.1 234.4 ± 38.2
Control -90.1 ± 0.7 103.4 ± 1.9 170.5 ± 15.3 156.9 ± 10.7 116.6 ±  13.1
Sotalol 52 µM -91.8 ± 0.6 105.8 ± 3.1 205.3 ± 21.6 244.3 ± 15.9 181.3 ± 21.5
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3.3.2.1. Effects of extracts and alkaloids of Chelidonium majus on hERG current 
 
For the investigations of hERG blocking effects of C. majus extracts, 25% and 45% ethanol 
(V/V) extracts were prepared with regard to the Assessment report EMA/HMPC/369801/2009 
on C. majus herb [53], which refers these extracts for internal use. Both extracts revealed 
significant hERG ion channel inhibitory activity at room temperature with estimated IC50 
values of 8.31 ± 0.79 μg/ml and 5.09 ± 0.49 μg/ml (Figure 18). 
 
 
Figure 18. Concentration-dependent effects of Chelidonium majus extracts on hERG current. Panel A depicted 
representative hERG current curves obtained from cell treated with 25% ethanol extract, while panel B shows the 
effect of 45% ethanol extract, both at 5 μg/ml concentration. Panel C shows the dose-response curves of the 25% 
ethanol extract and the 45% ethanol extract on hERG current. Estimated IC50 values are 8.31 ± 0.79 μg/ml and 
5.09 ± 0.49 μg/ml, respectively (n = 5). 
 
The hERG blocking potencies of the major alkaloids of the plant (sanguinarine, chelidonine, 
berberine and coptisine) were also evaluated and found that all alkaloids showed considerable 
inhibitory effect apart from coptisine (Figure 19). Sanguinarine and chelidonine were to have 
the highest inhibitory effect with the IC50 value of 0.88 ± 0.08 µM and 1.00 ± 0.10 µM, 
respectively. The hERG channel modulatory activity of berberine could be characterized by 
the IC50 value of 6.46 ± 0.54 µM, whereas coptisine exhibited only marginal effect 
(IC50 = 90.08 ± 2.88 µM). 
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Figure 19. Concentration-dependent inhibitory effects of Chelidonium majus derived alkaloids on hERG current. 
Panels A-D show representative hERG current curves obtained from cells treated with 1 µM sanguinarine (A), 
1 µM chelidonine (B), 10 µM berberine (C) and 100 µM coptisine (D). Panel E shows the dose-response curves 
of the examined alkaloids. Sanguinarine and chelidonine were the most effective with IC50 = 0.88 ± 0.08 µM and 
1.00 ± 0.10 µM, berberine IC50 was 6.46 ± 0.54 µM, while coptisine exhibited only marginal effect with 
IC50 = 90.08 ± 2.88 µM (n = 4-5). 
 
3.3.2.2. Effects of extracts and alkaloids of Chelidonium majus on ventricular action 
potential 
 
To investigate the safety pharmacology consequences of the hERG blocking effect of 
C. majus extracts and alkaloids the effect of these agents - with the exception of coptisine - on 
action potential configuration were studied in canine right ventricular muscle preparations. 
The results are presented in Table 4.  
Both extracts moderately extended the action potential duration at 5 μg/ml concentration in 
statistically significant manner at basic stimulation cycle length of 1000 ms. The prolongation 
of APD90 was 10.5% in case of the 25% ethanol extract while the 45% ethanol extract 
lengthened the action potential duration with 6.7%. The maximum rate of depolarization 
(Vmax) was not influenced significantly by the extracts. To study the rate-dependent effect of 
the extracts on APD90, the preparations were stimulated at cycle lengths ranging from 300 to 
5000 ms. Under these circumstances the extracts produced a slight reverse rate-dependent 
APD prolongation, especially in case of 45% extract (Figure 20).  
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Table 4. The electrophysiological effects of Chelidonium majus extracts in dog ventricular muscle preparations at 
basic cycle length of 1000 ms. RP, resting potential; APA, action potential amplitude; Vmax, maximum rate of 
depolarization; APD90 and APD50, action potential durations at 50% and 90% of repolarization. Results are 
mean ± SEM, n = 5-7. 
 
 
Figure 20. Effects of Chelidonium majus extracts (25% ethanol extract and 45% ethanol extract on panel A and 
B, respectively) on action potential waveform of dog ventricular muscle at stimulation cycle length of 1000 ms and 
rate-dependent effects on action potential duration (APD90). 
 
RP (mV) APA (mV) Vmax (V/s) APD90 (ms) APD50 (ms)
Control -85.4 ± 0.5 106.5 ± 2.3 258.0 ± 39.2 222.4 ±  6.4 178.9 ±  9.2
25% Ethanol extract 5 μg/ml -85.0 ± 0.8 106.0 ± 2.7 244.1 ± 39.9 246.5 ± 13.5 200.8 ± 14.9
Control -87.3 ± 0.5 106.3 ± 1.8 209.3 ± 25.6 226.0 ± 5.9 179.8 ±  7.2
45% Ethanol extract 5 μg/ml -85.8 ± 0.8 104.8 ± 1.2 245.3 ± 22.4 241.3 ± 8.8 186.2 ± 11.5
Control -86.8 ± 1.2 105.4 ± 3.0 250.6 ± 46.5 219.4 ± 6.6 181.6 ± 7.3
Berberine 1 µM -86.1 ± 0.9 107.6 ± 4.0 226.5 ± 44.6 233.1 ± 7.3 196.2 ± 6.6
Control -86.8 ± 1.0 107.3 ± 3.2 247.2 ± 39.4 223.1 ± 6.7 183.0 ± 6.4
Berberine 10 µM -86.1 ± 0.8 107.0 ± 2.5 247.9 ± 20.9 258.4 ± 8.5 215.5 ± 8.3
Control -88.8 ± 3.8 106.8 ± 2.8 174.4 ± 18.0 230.4 ± 17.6 180.6 ± 13.6
Chelidonine 1 µM -85.4 ± 1.4 108.7 ± 3.3 151.5 ±  9.0 240.1 ± 16.2 189.0 ± 11.4
Control -89.0 ± 3.7 106.9 ± 2.7 172.9 ± 18.7 219.6 ± 15.9 174.6 ± 14.0
Chelidonine 10 µM -85.9 ± 1.6 112.9 ± 3.2 197.8 ± 36.7 259.7 ± 17.7 204.8 ± 14.1
Control -89.0 ± 2.1 104.0 ± 2.6 230.1 ± 43.5 200.4 ±  9.3 156.4 ±  8.5
Sanguinarine 1 µM -87.6 ± 2.5 105.5 ± 4.3 242.8 ± 59.5 212.9 ± 11.9 170.9 ± 11.4
Control -86.8 ± 0.9 102.1 ± 3.0 169.2 ± 23.7 208.0 ± 12.2 172.2 ± 13.0
Sanguinarine 10 µM -85.8 ± 1.7 104.3 ± 1.7 142.3 ± 24.3 244.2 ±  6.2 202.5 ±  5.7
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The effects of berberine, chelidonine and sanguinarine on the action potential parameters at 
concentrations of 1 µM and 10 µM were also investigated in dog ventricular muscle at 
constant cycle length of 1000 ms (Table 4). All compounds showed mild but statistically 
significant effect on APD90 (4.6%, 6.1% and 6.3% prolongation, respectively) at 1 μM 
concentration. At 10 μM concentration the action potential prolongation was more 
considerable (18.4%, 18.3% and 16.0%). The rate-dependent effect of the alkaloids were also 
studied, where preparations were stimulated with different cycle lengths ranging from 300 to 
5000 ms. All examined alkaloids lengthened the action potential duration in reverse-rate 
dependent manner (Figure 21). 
 
 
Figure 21. Effects of Chelidonium majus alkaloids on action potential waveform of dog ventricular muscle at 
stimulation cycle length of 1000 ms and rate-dependent effects on action potential duration (APD90). Results of 
treatment with berberine, chelidonine and sanguinarine are shown on panel A, B and C, respectively. 
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4. DISCUSSION 
 
Measurement of the activity of individual ion channels became possible after the pioneering 
work of Erwin Neher and Bert Sakmann in the late 1970s. The manual patch-clamp method 
has rapidly become the ‘gold standard’ in investigating ion channels 
[2][3][5][7][9][10][12][25]. The patch-clamp technique offers a direct, information-rich and 
real-time technology, and provides excellent dynamic range for voltage control of the cell 
membrane, extraordinary temporal resolution (submillisecond) and sensitivity 
(subpicoampere). It also enables characterization of single channels in cell-attached, inside-
out, and outside-out configurations as well as total cell current in whole-cell configuration. 
Patch-clamp data can identify many aspects of drug-ion channel interaction, which is highly 
valuable and desirable during the selection and development of promising drug candidates 
[1][2][3][4][7][9][10]. On the other hand, traditional manual patch-clamp is too slow, 
technically demanding, and labor intensive, which excludes it as a screening tool in early drug 
development and optimisation. This does not mean that the conventional patch-clamp method 
is obsolete. Conventional patch-clamp is applied at the later stages of drug discovery and 
development and it still represents one of the primarily tools in ion channel research 
laboratories. In industry, the application of patch-clamp is limited to the end phases of drug 
research and ion channel screening and mainly used for final compound evaluation. These 
limitations are the fundamental reasons behind the held back of ion channel drug discovery 
and why ion channels have remained an unexploited area for the pharmaceutical industry 
[1][2][3][4][5][7][10][12]. 
Consequently, high-throughput techniques such as ligand binding, radioactive flux and 
fluorescence assays are also essential and become pivotal components for primary drug 
screening and ion channel drug discovery programmes. Although most of these techniques are 
compatible with the throughput requirements of primary screening, generally these 
approaches have low fidelity, low sensitivity and low temporal resolution (in the range of 
seconds to minutes, as compared to patch-clamp that operates in the submillisecond range) 
[2][3][4][5][7][9][10][11]. Due to the limitations of high-throughput techniques a secondary 
follow-up screening is required using methods that can provide more and detailed information 
like patch-clamp techniques to confirm ‘hits’ from the primary screening. Ideally, 
electrophysiological studies should be performed as early as possible in the drug discovery 
process, to acquire better information about the compound activity and efficacy, and also 
about possible safety liability issues [12]. 
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In recent years, many companies have developed and introduced automated patch-clamp 
equipments suitable for rapid and high quality screening and optimisation of ion channel drug 
candidates. By providing high quality, information rich assays, these appliances have the 
capability to bridge the gap between primary and secondary ion channel drug screening. 
Parallelisation of patch-clamp recordings permits higher throughput in characterisation of 
compounds and ion channels. These systems are able to generate large volumes of functional 
electrophysiological data in less time for screening and safety profiling, reducing the time to 
develop ion channel active drugs [1][2][3][4][10][12].  
Automated patch-clamp has resided mainly in the pharmaceutical industry with focus on 
recombinant cell lines induced to overexpress ion channels, while investigations of 
endogenous ion channels in native cells remain common and important in academic research 
[39]. Although automated patch-clamp systems are used mainly with recombinant cell lines 
we have found that Patchliner can produce high quality data from native cells and cells in 
primary culture, when the evaluation and characterization of the voltage-gated Kv1.3 K
+
 
channel was established in native activated human lymphocytes. Kv1.3 is one of the most 
important ion channels of human T lymphocytes and plays a fundamental role in antigen 
dependent activation and proliferation. Selective inhibition of Kv1.3 offers opportunities to 
modulate effector memory T cell responses in chronic inflammation or certain autoimmune 
diseases such as multiple sclerosis or rheumatoid arthritis, providing a therapeutic potential 
[50][54][55][56][57]. Three reference compounds were investigated, to test our automated 
patch-clamp system using these native cells. The IC50 value of tetraethylammonium, the 
classical small molecule blocker of many K
+
 channel was in the millimolar range 
(28.1 ± 3.1 mM). High affinity scorpion toxins anuroctoxin and margatoxin blocked the 
Kv1.3 channels in the low nano- or the picomolar range, fitting the dose-response relationship 
resulted in the IC50 values 25.4 ± 1.6 nM and 68.6 ± 16.7 pM, respectively. For quality 
assurance of our data, we compared them to manual patch-clamp data from literature. The 
half-blocking concentrations were described 10 mM for TEA [58], 0.73 nM for AnTx [59] 
and 10-50 pM for MgTx [50][60]. Our data are slightly elevated, but in good agreement with 
literature in case of TEA and MgTx. However, IC50 of AnTx was 35-fold higher with 
automated patch-clamp. Despite this discrepancy, Patchliner seems an appropriate tool for 
screening native lymphocytes, or even some other primary cells with acceptable success rate. 
However, automated patch-clamp systems mainly use stably expressing cell lines where the 
quality of the cell suspensions is fundamental for acceptable success rates. A cell is trapped 
randomly from the cell suspension; therefore a homogenous expression of ion channels 
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among cells is required within the suspension with cells of good quality and health. This blind 
approach for catching cells is the major reason why most platforms on the market not 
practicable to use primary or transiently transfected cells [1][2][11][12]. In addition, some 
approaches to automate two-electrode voltage-clamp recordings in the Xenopus oocyte 
expression system have been described like the Roboocyte (Multi Channel Systems) [61] and 
OpusXpress (Molecular Devices) [62]. These systems provide an option for multiple 
recordings in parallel towards higher throughput. Nevertheless, pharmacological results 
created using oocytes were not usually comparable with mammalian data, because of the 
different membrane components and structure, and therefore the field has focused greatly on 
automated systems for mammalian cells using planar-array based approaches [1][5]. 
There are many advantages of the gene-centric approach in which a target protein is 
overexpressed in recombinant mammalian cell lines. These cell lines are relatively easy to 
culture and are robust enough to be handled by automated screening platforms. The protein of 
interest can be overexpressed in these systems, elevating the current level and improving the 
signal-to-noise ratio. However, host cells with null or very low background conductance can 
be chosen to enable very sensitive assays of ion channels, and allows to be certain of the 
molecular identity of the gene accountable for the observed signal [63]. The major 
disadvantage of using non-native cell lines for electrophysiological measurements is that the 
cell is not the physiological target and the responses may differ from those that occur in vivo. 
The evaluation and characterization of cell lines stably expressing GABA, HCN, GIRK, 
Kv1.4 and hERG channels were performed in our studies. The GABA receptor family is the 
major class of inhibitory ion channels in central nervous system. GABAA chloride channels 
considered as important therapeutic region for drugs affecting anxiety, influencing sleep 
processes and treating epilepsy [64][65][66][67][68][69][70][71]. Using the Patchliner 
platform, HEK-cells expressing GABAA ligand-gated ion channel were studied utilizing a 
stacked solution application for quick and precise administration of compounds to the patch-
clamped cells. The EC50 value for GABA was determined to 32.20 ± 1.85 µM, which is fairly 
close to manual patch-clamp data on recombinant HEK cell lines (12-53 µM) [72][73]. In the 
further experiments, we applied the ~EC20 concentration of GABA (10 μM), to which the 
repeated addition does not desensitized the channels, and the effect of the antagonist 
bicuculline was studied. The estimated IC50 value of this inhibitor (371.06 ± 3.43 nM) 
corresponds very well to the literature (0.1-2.7 μM) [74][75][76][77][78], reflecting the 
suitability of Patchliner for GABAA investigations. Like most ligand-gated channels, GABAA 
presents receptor desensitization, which is an ordinary phenomenon among ligand-gated ion 
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channels. Exposure time, concentration, and application intervals are main factors affecting 
desensitization and recovery. For rapidly desensitizing channels, quick compound application 
is also essential, so that the whole ion channel population is exposed to maximum 
concentration before entering the desensitized state. In our study, within a cycle the cells were 
exposed to 10 µM GABA for 5 s, followed by a 3 minutes wash step. Solution exchange in 
the environment of the cell was rapid, approximately 50-100 ms for the concentrations. In this 
way, receptor desensitization can be minimized, and effects of co-applied drugs can be tested. 
Moreover, this method for stacked solution application, allowing short pulses of compound is 
convenient for the measurements not only GABAA-receptor, but for most ligand-gated ion 
channels. 
Among the investigated voltage-gated ion channels, HCN (hyperpolarization-activated cyclic 
nucleotide-gated) channels are the molecular determinants of the pacemaker or funny current 
(If) in the heart. They are largely expressed in spontaneously active cardiac zones, such as the 
sinoatrial node, and regulate the activity rate of myocytes. Four isoforms of this channel 
(HCN1-4) are known; from these we investigated the HCN1 and HCN4 isoforms. Due to the 
creation of pacemaker activity and the modulation of spontaneous frequency, HCN channels 
are potential targets of drugs aimed to pharmacologically manage heart rate 
[79][80][81][82][83][84][85][86][87]. In these cell lines, the detected currents had very small 
amplitudes under physiological conditions; therefore, 25 mM extracellular K
+
 concentration 
was chosen for use, which was found to be the lowest one providing a current on which 
changes can be safely detected. We performed the evaluation of HCN1 and HCN4 cell lines 
on Patchliner by applying ivabradine, the most specific and selective If inhibitor [88][89]. 
10 µM ivabradine reduced HCN1 and HCN4 currents by 64.52 ± 5.36%  and 63.79 ± 1.07%, 
respectively, showing almost similar but slightly weaker effects than literature data (the half 
block concentrations with manual patch-clamp were 0.9 and 2.0-2.1 µM for HCN1 and HCN4 
on HEK cell line, and the IC50 for the block of If was 2.2-2.9 µM in isolated myocytes) 
[88][90][91][92]. 
G protein-coupled inwardly rectifying potassium channels (GIRK1/4, Kir3.1/3.4), which 
activated by the release of acetylcholine from the vagus nerve, are selectively expressed in the 
cardiac atrium and they are not present in the ventricle. Electrical remodelling of atrial heart 
muscle during chronic atrial fibrillation may result in a constitutively active form of GIRK 
channel which reflects the main role of this channel in this disease. Therefore, selective 
inhibition of GIRK channel might be a useful tool in the treatment of atrial fibrillation, devoid 
of serious ventricular side effects [51][93][94][95]. As with HCN channels, external solution 
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containing 25 mM K
+
 was chosen for use in our GIRK experiments, since this was found to 
be the lowest K
+
 level providing a current on which the current changes can be safely 
detected. Several reference compounds were investigated on this channel to allow comparison 
between manual and automated patch-clamp data. Six reference compounds were measured at 
room temperature, where also the compound screenings were established. Chloroquine, a drug 
used in the treatment or prevention of malaria described to inhibit the native acetylcholine 
receptor operated potassium current (IKACh) in isolated guinea pig atrial myocytes with 
0.7-0.8 μM IC50 values, which is similar to our result (463.70 ± 34.61 nM) [96]. Quinidine, 
which acts as a class I antiarrhythmic agent and also indicated for treatment of malaria, 
reported to block IKACh with 1.8-21 μM IC50 values [96]. These are also in good agreement 
with the 5.04 ± 0.62 μM value defined by Patchliner. Effect of a novel cardioprotective drug, 
JTV-519, on IKACh currents of guinea pig atrial cells was also described [97]. JTV-519 
inhibited IKACh with the IC50 values of 0.12-2.42 μM, in conformity with our automated patch-
clamp data (814.24 ± 109.34 nM). We examined the effect of NIP-142, a multiple ion channel 
blocker for the treatment of atrial fibrillation. NIP-142 was described to concentration-
dependently blocked the human G protein-coupled inwardly rectifying potassium channel 
current expressed in HEK cells with an IC50 value of 0.64 μM [98]. This is in the same order 
of magnitude with our findings (175.75 ± 8.59 nM). Propafenone is used to treat illnesses 
associated with rapid heartbeats such as atrial and ventricular arrhythmias. It was reported to 
block the acetylcholine induced K
+
 current (IKACh) in dissociated guinea pig atrial myocytes 
under whole-cell voltage-clamp. The values of half-maximal inhibition were 0.2-0.7 μM [99]. 
Likewise, we measured propafenone exert its effect with 372.99 ± 27.69 nM IC50 value on 
HEK-GIRK cells using Patchliner. Inhibition of GIRK channel by the antidepressant drug 
desipramine was also concentration-dependent with an IC50 value of 1.47 ± 0.17 μM. No 
literature data are available in native or cultured mammalian cells in this topic. The well-
known class III antiarrhythmic agent amiodarone and its major metabolite 
desethylamiodarone were investigated at physiological temperature (37°C). They blocked 
GIRK current with nearly identical 1.77 ± 0.18 and 1.82 ± 0.15 μM IC50 values, in good 
correlation with literature (IC50 for amiodarone around 2 µM in isolated guinea pig atrial 
myocytes) [100].  
Based on these data, which reflect the pharmacology between manual and automated patch-
clamp platform Patchliner was similar for most reference compounds in case of GIRK cell 
line, screening of preselected chemical libraries and compounds and extracts originated from 
natural sources was performed in order to discover new and effective medicaments for the 
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treatment of atrial fibrillation. The screening project of chemical libraries resulted in four 
promising compounds, which dose-response curves and IC50 values were determined in 
detailed experiments on both GIRK and hERG channels. Ryt-243 showed similar inhibitory 
effect on GIRK and hERG channels: IC50 values were 100.14 ± 5.10 nM and 
47.56 ± 5.31 nM, respectively. The other 3 compounds (Ryt-143, Ryt-144 and Ryt-230) 
revealed an at least 10 times higher blocking effect on GIRK channels compared to hERG. As 
hERG blocking effect can be even useful in antiarrhythmic treatment Ryt-243 was subjected 
to further investigations. Despite of its hERG blocking activity, Ryt-243 did not prolong the 
action potential in rabbit ventricular muscle either in 5 µM or in 10 µM concentrations. A 
potential explanation to this phenomenon is that this agent has multichannel effect and also 
blocks other ion channel(s) during cardiac action potential repolarization. Ryt-243 was also 
investigated in dog model, and the compound had a strong antiarrhythmic effect. Based on 
these antiarrhythmic results a patent was filed in which anti-atrial fibrillation effects of 
Ryt-243 are chartered. Compounds showing GIRK-selectivity (Ryt-143, Ryt-144 and Ryt-
230) are also involved in further ongoing investigations including antiarrhythmic effect 
evaluation and structure-effect analysis. 
Compounds originated from natural sources were also investigated in GIRK screen project. 
These natural plant compounds were chosen randomly and were not preselected. 
Approximately 9% of the investigated natural molecules showed a notable (i.e. at least 50% 
decrease in the GIRK current at 10 μM concentration) blocking effect. In comparison, in case 
of chemical libraries, 10% of the revised chemical libraries were preselected as possible 
potent structures and were investigated, and 13% of the selected compounds showed at least 
50% inhibitory effect on GIRK current at 10 μM concentration, reflecting the high hit rate of 
the natural compounds. 
Testing a new way of tracing biologically active compounds extracts of Polygonum persicaria 
were also investigated in our GIRK screen system, with the aim to identify natural sources of 
promising ion channel blocking compounds [52]. To the best of our knowledge, GIRK 
inhibitory assay was used for the first time for screening plant extracts for potassium ion 
channel blockers. In this study the GIRK channel inhibitory activity of the chloroform extract 
of Polygonum persicaria was demonstrated, and new natural flavonoids were identified from 
the extract. Unfortunately, the isolated compounds have only moderate activities on GIRK 
channel; therefore further studies are needed in order to identify minor compounds 
responsible for the potassium ion channel modulatory activity. 
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Kv1.4 is a voltage-gated potassium channel, which open on membrane depolarization and 
inactivate rapidly. Kv1.4 channel underlie the cardiac transient outward potassium current 
(Ito) in cardiac muscle. It is important in the regulation of the fast repolarizing phase of action 
potentials in heart and thus may influence the duration of cardiac action potential 
[101][102][103]. This cell line had relatively high currents in the nanoamper range. Both 
tested reference compound blocked the current. IC50 values for chromanol 293B and 
4-aminopyridine were 85.69 ± 8.38 μM and 791.33 ± 26.84 μM, respectively. According to 
literature data, chromanol 293B blocked transient outward current Ito with an IC50 of 38 μM in 
canine left ventricular cells [104]. The IC50 of 4-aminopyridine on Ito was 0.64-0.67 mM in 
atrial myocytes isolated from human hearts and 0.28 mM in rabbit sino-atrial node cells 
[105][106][107]. All these data are in good agreement with our results on Kv1.4 cell line. 
Based on our results, several natural plant compounds were selected for further evaluation 
following the primary screen on GIRK channel. These agents were also tested on 
Kv1.4 cell line and selectivity of their GIRK blocking effect was evaluated with these 
experiments. 
Besides the ion channel drug screening to discover and develop new and more effective drugs, 
another important aspect of the application of automated patch-clamp systems is the safety 
pharmacology. Life threatening cardiac arrhythmias and sudden cardiac death caused by 
drugs are one of the major safety issues for pharmaceutical industry and regulatory agencies. 
In recent years, several drugs such as terfenadine, cisapride, grepafloxacin and terodiline have 
been withdrawn from major markets because of their proarrhythmic effect related to the 
lengthening of cardiac repolarization manifested as QT interval lengthening on the surface 
ECG. This cardiac proarrhythmic effect of different compounds is attributed to their ability to 
block the rapid delayed rectifier K
+
 current (IKr). Based on this concept investigation of IKr 
blocking and action potential duration lengthening capabilities became of required item of 
safety pharmacology profile of new compounds [1][2][4][7][12][13][14]. However those tests 
are complicated and time consuming. Therefore analysis of IKr current in heart muscle cells 
was replaced by the examination of its recombinant equivalent hERG current (Kv11.1). 
Although hERG assay as a high-throughput technique is very powerful but sometimes gives 
false positive and negative results. The mechanism of the occasional failure of the hERG test 
is not well understood. Therefore we have compared the effect of dofetilide and sotalol on 
hERG current (at room temperature and 37°C) and on IKr current (37°C) and determined the 
value of hERG current measurements in evaluation of cardiac proarrhytmic risk of 
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compounds and helping the understanding of mechanism of proarrhythmic pharmacological 
safety drug tests. 
Current responses of cells expressing the hERG channel at room temperature and 
physiological temperature were similar in case of dofetilide. The most noticeable effects of 
raising the temperature to 37°C was that the peak amplitude was increased, the rise time was 
decreased and the time constant of decay phase was faster. Despite that, the dose-response 
curve generated an IC50 similar to that obtained at room temperature, and similar to that 
determined in the IKr experiments (8.41 ± 0.19 nM, 7.29 ± 0.16 nM and 13.02 ± 2.56 nM, 
respectively). Additionally, these data are in good agreement with our action potential 
measurements (13 nM dofetilide prolonged the APD90 with 47.8 ± 12.9 %) and with literature 
data [108][109][110][111][112][113][114]. 
Conversely, sotalol displays not only different kinetics but different potencies at room 
temperature and 37°C. Sotalol has been shown to block hERG channels at room temperature 
with an IC50 of 773.74 ± 9.28 μM. However, at physiological temperature sotalol was more 
potent (IC50 = 342.84 ± 24.82 μM) and therefore, it is a desirable option to study ion channels 
at physiological temperature since compounds can exhibit different actions or potencies at 
37°C. For safety screening, it may be particularly critical to test compounds at physiological 
temperature and this makes the Patchliner an ideal instrument for these experiments. 
Moreover, in case of sotalol, a significant difference was observed between the hERG IC50 
values and the IC50 value on IKr current. The IC50 on IKr on ventricular myocytes was 
calculated to be 51.60 ± 9.82 μM, and accordingly this concentration of sotalol lengthened the 
action potential with 56.0 ± 4.6 %. 
Based on our experiments, results obtained with automated patch-clamp equipment in HEK-
hERG cells often show a reasonable conformity with outcomes of IKr current measurements. 
However there are important and not well understood differences between the evaluation of 
hERG-blocking ability with automated patch-clamp and other techniques such as the IKr or 
action potential experiments. In manual patch-clamp, test solutions are usually prepared in 
relatively large quantities directly before the experiments, and are continuously perfused. In 
automated platforms, compound plates with minor volume are used, and comparatively small 
volumes of test solutions are applied to the cells. The adverse surface-to-volume ratio in 
compound plates and microchannels and the increased incubation time can lead to possible 
reduction of compound concentrations, especially in case of hydrophobic, ‘sticky’ agents such 
as astemizole or terfenadine. Adhesion and precipitation have been identified as the major 
sources of potential right-shifted less accurate dose-response curves [37][109][115]. 
50 
 
Nevertheless, sotalol is among the least hydrophobic compounds [109], and numerous studies 
also reported extremely high IC50 values in hERG cell lines utilized for manual patch-clamp 
(the half-blocking concentrations of sotalol were 137-1200 μM in these experiments) 
[14][116][117][118][119][120].  
Increasing evidence indicates that the composition of native IKr channels is very complex, and 
the α-subunit composition of the channel can affects its sensitivity to block. The hERG1 gene 
encodes at least two transcripts: hERG1a, the original isolate, and hERG 1b, an alternate 
transcript [121][122]. The most of hERG screens have been conducted using recombinant cell 
lines expressing the hERG 1a subunit, although native ventricular IKr channels are heteromers 
containing both hERG 1a and 1b subunits [123]. Although the potency of most compounds 
(including sotalol) was similar for the two targets, some differences were observed. Some 
drugs was more potent at blocking hERG 1a/1b than 1a channels, others were a more potent 
blocker of hERG 1a compared with 1a/1b channels. Thus the existing hERG 1a assays may 
underestimate the risk of some drugs and overestimate the risk of others [13][124]. In 
addition, other studies have identified interacting proteins affecting hERG drug sensitivity. 
For example, MinK, MiRP1 and KCR1 coassembles with a pore-forming subunit to create 
stable complexes whose functional attributes resemble those of a native cardiac potassium 
channel, adding another level of complexity to the control mechanisms affecting cardiac 
electrophysiology. Their expression and modulation by drugs could play an important role in 
determining the amount and character of the IKr current in individual cardiac myocytes 
[114][125][126][127]. 
Since the results of hERG measurements - in spite of their beneficial time/cost value and 
popularity - are not as adequate as it previously thought the estimation of proarrhytmic 
liability by hERG assays can be handled only with precaution. The cellular and molecular 
base of the techniques applied in these types of safety pharmacology investigations needs 
further explorative work. 
Based on these experiences, safety pharmacology studies of Chelidonium majus were 
achieved, where the effects of extracts and alkaloids of the plant were investigated on hERG 
current as well as on ventricular action potential. In our electrophysiological study we 
investigated C. majus herb hydroalcoholic extracts and its four benzylisoquinoline alkaloids, 
berberine and coptisine from protoberberines subgroup, and chelidonine and sanguinarine 
from benzophenanthridines subgroup using patch-clamp method and conventional 
microelectrode technique. Both 25% and 45% ethanol extracts were prepared according to the 
Assessment report EMA/HMPC/369801/2009 on Chelidonium majus herb. These extracts 
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which have a long tradition of internal application against a wide scale of different diseases, 
possess hERG channel inhibition and prolongs the duration of cardiac action potential. In this 
work, to the best of our knowledge, we report the first experimental evidence of hERG 
potassium channel blocking and action potential prolonging effect of C. majus herb 25% and 
45% ethanol extracts. Moreover, the effect of chelidonine and sanguinarine on action 
potential was investigated for the first time. The examined substances not only inhibit the 
hERG current, but also extend the duration of the action potential. In certain 
pathophysiological conditions where repolarization reserve is impaired [128][129] all of these 
alkaloids may have additive effects further increasing the possibility of proarrhythmic risk 
and cardiac sudden death. In conclusion, the internal use of C. majus extracts or its alkaloids, 
berberine, chelidonine and especially sanguinarine in some situations where cardiac 
repolarization reserve is weak may increase the risk of potentially fatal ventricular 
arrhythmias. These findings are likely to contribute significantly to clear the complex 
cardiotoxic effects of C. majus, and reflect the potential cardiac risk of the usage of this herb. 
Our results highlight the safety concerns regarding the internal use of C. majus: orally applied 
greater celandine products need cautious evaluation from the view of cardiovascular side 
effects. 
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5. CONCLUSIONS 
 
1. The fully automated patch-clamp platform Patchliner provides high data quality and 
robust recordings. The Patchliner is compatible with many different cell lines, most 
often showing little discrepancy between the results obtained with automated and 
manual patch-clamp methods. Because of the elevated throughput and high success 
rate obtained in our experiments the Patchliner proved to be an excellent tool in 
cellular electrophysiological experiments and we positively suggest its use both in 
academic and pharmaceutical industrial research.  
2. Several cell lines were characterized and used in screening projects of preselected 
chemical libraries performed with Patchliner. Based on these screening results a patent 
was filed in which anti-atrial fibrillation effects of Ryt-243 are chartered.  
3. Compounds originated from natural (plant) sources were also involved in GIRK 
screen project. Our studies reflect the outstandingly high hit rate of compounds 
originated from natural sources. 
4. To the best of our knowledge, GIRK inhibitory assay was used for the first time for 
screening of plant extracts for inhibitors, with the aim to identify natural sources of 
promising ion channel blocking compounds.  
5. In safety pharmacology studies, we showed important and not well understood 
differences between the hERG-blocking ability of different compounds evaluated with 
automated patch-clamp method or other techniques such as IKr experiments with 
manual patch-clamp or action potential studies. We demonstrated that the estimation 
of proarrhytmic liability by hERG assays is not as adequate as it was previously 
thought and can be handled only with precaution.  
6. Our electrophysiological studies on extracts and alkaloids of Chelidonium majus herb 
revealed that the plant possess hERG channel inhibition and prolong the duration of 
cardiac action potential. These results may contribute to the understanding of the toxic 
effects of C. majus and highlight the potential cardiac risk of the usage of this herb. 
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